Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model
研究表明,RiskScore是乳腺癌风险的更准确预测指标,其准确性是Tyrer-Cuzick模型的两倍
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk Hereditary Cancer Test with RiskScore study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute.
盐湖城,2024年12月19日(全球新闻社)—— 万基遗传(NASDAQ: MYGN),一家在遗传和基因组检测及精准医疗领域的领导者,宣布其MyRisk遗传癌症测试与RiskScore的研究被《美国人类遗传学杂志》评选为基因组医学的十大重要进展之一。该研究由国家人类基因组研究所的基因组医学工作组选出。
The study by Mabey et al., "Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors," presented a longitudinal clinical validation of MyRisk with RiskScore using data from more than 130,000 women referred for hereditary cancer genetic testing.
Mabey等人的研究,"结合多基因得分与传统风险因素的临床乳腺癌风险评估工具的验证,"展示了使用超过130,000名接受遗传癌症基因检测女性的数据,对MyRisk与RiskScore进行的纵向临床验证。
RiskScore integrates a polygenic risk score (PRS) for all ancestries with the widely used Tyrer-Cuzick model. The study demonstrated that Myriad's PRS is a more accurate predictor of breast cancer risk than Tyrer-Cuzick alone. In fact, RiskScore delivered two times the ability to predict breast cancer risk than the Tyrer-Cuzick model. Additionally, Myriad was one of the first commercial laboratories to market with a multi-ancestry breast-cancer PRS, driven by its mission to advance health equity and deliver more inclusive genetic insights.
RiskScore将适用于所有血统的多基因风险评分(PRS)与广泛使用的Tyrer-Cuzick模型相结合。研究表明,万基的PRS比单独的Tyrer-Cuzick模型更准确地预测乳腺癌风险。实际上,RiskScore的乳腺癌风险预测能力是Tyrer-Cuzick模型的两倍。此外,万基是首批推出具有多血统乳腺癌PRS的商业实验室之一,这一举措旨在推进健康公平并提供更具包容性的基因洞察。
"We are honored by this recognition, which underscores the clinical significance of the validation research from the study and predictive accuracy of RiskScore," said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. "MyRisk with RiskScore can assist both clinicians and patients in making informed, proactive medical management decisions to help prevent breast cancer or detect it early. The accuracy of RiskScore across all ancestries emphasizes Myriad's commitment and contribution to health equity."
"我们很荣幸获得这一认可,这强调了该研究的验证研究的临床重要性和RiskScore的预测准确性,"万基遗传首席科学官Dale Muzzey博士说。"MyRisk与RiskScore可以帮助临床医生和患者做出明智、主动的医疗管理决策,以帮助预防乳腺癌或早期发现。RiskScore在所有血统上的准确性强调了万基对健康公平的承诺和贡献。"
"We hope that the selection of our paper as a major advance will continue to drive the adoption of RiskScore by providers and guideline societies," continued Muzzey.
“我们希望我们的论文被选为重大进展能够继续推动提供者和指南协会采用RiskScore。”穆泽说。
About MyRisk Hereditary Cancer Test with RiskScore
MyRisk Hereditary Cancer Test with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment individualized to them.
关于MyRisk遗传癌症测试与RiskScore
MyRisk遗传癌症测试与RiskScore评估48个与遗传癌症风险相关的基因,以识别与11种不同癌症相关的遗传变化。当与家族史和其他临床因素(如乳腺密度)结合时,MyRisk与RiskScore为符合条件的患者提供个性化的五年和剩余生命周期乳腺癌风险评估。
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .
关于Myriad Genetics
万基遗传是一家领先的基因检测和精准医疗公司,致力于提升所有人的健康和幸福。万基开发并提供基因检测,帮助评估患病风险或疾病进展,并在医疗专业领域指导治疗决策,在这些领域,基因洞察可以显著改善患者护理并降低医疗成本。欲了解更多信息,访问。
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that MyRisk with RiskScore being featured as a top innovation in genomic medicine reinforces the need for more wide-scale clinical implementation of MyRisk with RiskScore, as this data is likely to have implications for healthcare systems and practice guidelines, and MyRisk with RiskScore can assist both clinicians and patients in making informed, proactive medical management decisions to help prevent breast cancer or detect it early. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
安全港声明
本新闻稿包含1995年《私人证券诉讼改革法》所指的“前瞻性声明”,其中包括MyRisk与RiskScore作为基因医学的顶级创新被突出介绍,强化了广泛临床实施MyRisk与RiskScore的必要性,因为这些数据可能对医疗系统和实践指南产生影响,而MyRisk与RiskScore可以帮助临床医生和患者做出明智的、积极的医疗管理决策,以预防乳腺癌或早期发现乳腺癌。这些“前瞻性声明”是管理层截至本日期对未来事件的预期,并且受到已知和未知的风险和不确定性的影响,这些因素可能导致实际结果、条件和事件显著地及不利地与预期的不同。这些因素包括公司向美国证券交易委员会提交的文件中描述的那些风险,包括公司于2024年2月28日提交的10-K表格年度报告,以及不时在公司的10-Q表格季度报告或8-K表格当前报告中提交的这些风险因素的任何更新。万基遗传没有任何义务,也明确否认任何义务去更新或更改任何前瞻性声明,无论是由于新信息、未来事件还是其他情况,除非法律要求。
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
投资者联系
马特·斯卡洛
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
媒体联系
格伦·法雷尔
(385) 318-3718
PR@myriad.com
评论(0)
请选择举报原因